The C-suite has been restructured and the positions occupied by Gisela Paulsen, President and COO, and Douglas Ross, Chief Scientific Officer, will be eliminated. Oncocyte expects that Ms. Paulsen and Dr. Ross will serve as advisors during a transition phase over the next quarter.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OCX:
- Oncocyte Announces Initiatives to Focus Corporate Strategy
- OncoCyte downgraded to Hold from Buy at Lake Street
- Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
- Oncocyte Announces Executive Leadership Changes
- OncoCyte CEO Ronnie Andrews to step down, Joshua Riggs named interim CEO
